(JNJ) Johnson & Johnson - Ratings and Ratios
Pharmaceuticals, Medical Devices, Consumer Health, Vision Care, Orthopaedics
JNJ EPS (Earnings per Share)
JNJ Revenue
Description: JNJ Johnson & Johnson September 24, 2025
Johnson & Johnson (NYSE: JNJ) is a diversified global health-care company that develops, manufactures, and sells a broad portfolio of pharmaceuticals, medical devices, and consumer-health products through its two primary operating segments: Innovative Medicine and MedTech.
The Innovative Medicine segment covers a wide range of therapeutic areas, including immunology (e.g., rheumatoid arthritis, psoriasis), infectious diseases (notably HIV/AIDS), neuroscience (mood and neurodegenerative disorders), oncology (prostate, lung, bladder, and hematologic cancers), cardiovascular/metabolism (thrombosis, diabetes, macular degeneration), and pulmonary hypertension. These products are distributed to wholesalers, hospitals, retailers, and health-care professionals for prescription use.
The MedTech segment supplies electrophysiology systems for heart-rhythm disorders, high-risk percutaneous coronary interventions and cardiogenic-shock support, calcified-coronary and peripheral-artery disease solutions, and neuro-vascular devices for stroke. It also offers orthopaedic implants (hips, knees, spine), advanced surgical tools, breast-reconstruction technologies, ACUVUE contact lenses, and TECNIS intra-ocular lenses for cataract surgery, reaching hospitals, clinics, eye-care professionals, and retail channels.
Key financial indicators (FY 2023) include ≈ $79.9 billion in revenue, a 13% increase in R&D spending to roughly $13 billion, and a dividend yield near 2.9 %-both of which reflect the company’s commitment to pipeline growth and shareholder returns. The stock’s price-to-earnings multiple has hovered around 15×, modestly below the long-term industry average, suggesting relative valuation attractiveness.
Sector-wide drivers that could materially affect JNJ’s outlook are the continued rise in global health-care spending (U.S. expenditures grew ~6% YoY in 2023), an aging population that fuels demand for chronic-disease therapeutics and orthopaedic devices, and the pressure from biosimilar competition that compresses margins in the pharmaceutical space. Conversely, MedTech growth is supported by increasing procedural volumes and the shift toward minimally invasive interventions.
For a deeper quantitative breakdown of JNJ’s valuation metrics and scenario analysis, see the ValueRay platform.
JNJ Stock Overview
| Market Cap in USD | 455,477m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1944-09-24 |
JNJ Stock Ratings
| Growth Rating | 51.0% |
| Fundamental | 80.2% |
| Dividend Rating | 62.2% |
| Return 12m vs S&P 500 | 6.50% |
| Analyst Rating | 3.75 of 5 |
JNJ Dividends
| Dividend Yield 12m | 3.43% |
| Yield on Cost 5y | 5.04% |
| Annual Growth 5y | 5.39% |
| Payout Consistency | 86.1% |
| Payout Ratio | 49.5% |
JNJ Growth Ratios
| Growth Correlation 3m | 81.2% |
| Growth Correlation 12m | 83.1% |
| Growth Correlation 5y | 35.7% |
| CAGR 5y | 5.55% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.32 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.69 |
| Sharpe Ratio 12m | 1.38 |
| Alpha | 11.94 |
| Beta | 0.392 |
| Volatility | 16.06% |
| Current Volume | 6767.4k |
| Average Volume 20d | 7764.4k |
| Stop Loss | 181.3 (-3%) |
| Signal | 0.09 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (25.12b TTM) > 0 and > 6% of Revenue (6% = 5.53b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -1.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.06% (prev 1.70%; Δ 2.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 24.20b <= Net Income 25.12b (YES >=105%, WARN >=100%) |
| Net Debt (-11.84b) to EBITDA (39.56b) ratio: -0.30 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.43b) change vs 12m ago 0.03% (target <= -2.0% for YES) |
| Gross Margin 68.08% (prev 69.05%; Δ -0.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.66% (prev 49.19%; Δ 0.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 48.23 (EBITDA TTM 39.56b / Interest Expense TTM 667.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.56
| (A) 0.02 = (Total Current Assets 54.61b - Total Current Liabilities 50.87b) / Total Assets 192.82b |
| (B) 0.87 = Retained Earnings (Balance) 167.28b / Total Assets 192.82b |
| warn (B) unusual magnitude: 0.87 — check mapping/units |
| (C) 0.17 = EBIT TTM 32.17b / Avg Total Assets 185.55b |
| (D) 1.37 = Book Value of Equity 155.16b / Total Liabilities 113.54b |
| Total Rating: 5.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.19
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 4.30% = 2.15 |
| 3. FCF Margin 20.69% = 5.17 |
| 4. Debt/Equity 0.08 = 2.50 |
| 5. Debt/Ebitda -0.30 = 2.50 |
| 6. ROIC - WACC (= 10.69)% = 12.50 |
| 7. RoE 32.69% = 2.50 |
| 8. Rev. Trend 49.95% = 3.75 |
| 9. EPS Trend 12.49% = 0.62 |
What is the price of JNJ shares?
Over the past week, the price has changed by -1.10%, over one month by -0.63%, over three months by +10.41% and over the past year by +22.25%.
Is Johnson & Johnson a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JNJ is around 183.31 USD . This means that JNJ is currently overvalued and has a potential downside of -1.96%.
Is JNJ a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 13
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JNJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 199.6 | 6.7% |
| Analysts Target Price | 199.6 | 6.7% |
| ValueRay Target Price | 202.3 | 8.2% |
JNJ Fundamental Data Overview November 01, 2025
P/E Trailing = 18.2483
P/E Forward = 16.4204
P/S = 4.9428
P/B = 5.7077
P/EG = 1.0724
Beta = 0.392
Revenue TTM = 92.15b USD
EBIT TTM = 32.17b USD
EBITDA TTM = 39.56b USD
Long Term Debt = 30.65b USD (from longTermDebt, last fiscal year)
Short Term Debt = 6.39b USD (from shortTermDebt, last quarter)
Debt = 6.39b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -11.84b USD (from netDebt column, last quarter)
Enterprise Value = 443.30b USD (455.48b + Debt 6.39b - CCE 18.56b)
Interest Coverage Ratio = 48.23 (Ebit TTM 32.17b / Interest Expense TTM 667.0m)
FCF Yield = 4.30% (FCF TTM 19.06b / Enterprise Value 443.30b)
FCF Margin = 20.69% (FCF TTM 19.06b / Revenue TTM 92.15b)
Net Margin = 27.26% (Net Income TTM 25.12b / Revenue TTM 92.15b)
Gross Margin = 68.08% ((Revenue TTM 92.15b - Cost of Revenue TTM 29.42b) / Revenue TTM)
Gross Margin QoQ = 69.56% (prev 67.87%)
Tobins Q-Ratio = 2.30 (Enterprise Value 443.30b / Total Assets 192.82b)
Interest Expense / Debt = 0.28% (Interest Expense 18.0m / Debt 6.39b)
Taxrate = 31.24% (2.34b / 7.49b)
NOPAT = 22.12b (EBIT 32.17b * (1 - 31.24%))
Current Ratio = 1.07 (Total Current Assets 54.61b / Total Current Liabilities 50.87b)
Debt / Equity = 0.08 (Debt 6.39b / totalStockholderEquity, last quarter 79.28b)
Debt / EBITDA = -0.30 (Net Debt -11.84b / EBITDA 39.56b)
Debt / FCF = -0.62 (Net Debt -11.84b / FCF TTM 19.06b)
Total Stockholder Equity = 76.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.03% (Net Income 25.12b / Total Assets 192.82b)
RoE = 32.69% (Net Income TTM 25.12b / Total Stockholder Equity 76.84b)
RoCE = 29.93% (EBIT 32.17b / Capital Employed (Equity 76.84b + L.T.Debt 30.65b))
RoIC = 18.05% (NOPAT 22.12b / Invested Capital 122.57b)
WACC = 7.36% (E(455.48b)/V(461.86b) * Re(7.46%) + D(6.39b)/V(461.86b) * Rd(0.28%) * (1-Tc(0.31)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.04%
[DCF Debug] Terminal Value 78.16% ; FCFE base≈19.24b ; Y1≈19.07b ; Y5≈19.88b
Fair Price DCF = 146.2 (DCF Value 352.28b / Shares Outstanding 2.41b; 5y FCF grow -1.62% → 3.0% )
EPS Correlation: 12.49 | EPS CAGR: 6.58% | SUE: 0.55 | # QB: 0
Revenue Correlation: 49.95 | Revenue CAGR: 0.44% | SUE: 0.51 | # QB: 0
Additional Sources for JNJ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle